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Abstract. Japanese encephalitis virus (JEV) is the leading cause of pediatric viral neurological disease in Asia. The JEV-
specific IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) in cerebrospinal fluid (CSF) and serum
is the recommended method of laboratory diagnosis, but specificity of JEV MAC-ELISA can be low due to cross-reactivity.
To increase the specificity of the commercially available JE Detect™ MAC-ELISA (JE Detect), a differential testing algo-
rithm was developed in which samples tested by JE Detect with positive results were subsequently tested by the DEN
Detect™ MAC-ELISA (DEN Detect) kit, and results of both tests were used to make the final interpretation. The testing
algorithm was evaluated with a reference panel of serum and CSF samples submitted for confirmatory testing. In serum, the
false Japanese encephalitis (JE) positive rate was reduced, but sequential testing in CSF resulted in reduced JE specificity, as
true JEV+ CSF samples had positive results by both JE Detect and DEN Detect and were classified as JE− (dengue virus
[DENV]+). Differential diagnosis of JE by sequential testing with JE Detect and DEN Detect increased specificity for JE in
serum, but more data with CSF is needed to make a final determination on the usefulness of this testing algorithm for CSF.
INTRODUCTION
Japanese encephalitis virus (JEV) is the leading cause of viral
neurological disease and disability in children under 15 years
in Asia, with an estimated 68,000 cases annually, 20–30% of
which are fatal.1 Approximately 30–50% of survivors have
long-term sequelae.2 Neurological symptoms of JEV infection
may be similar to those caused by other viral and bacterial
pathogens, which makes laboratory-based diagnosis essential
for guiding treatment or control strategies or both of this
vaccine-preventable disease and other treatable infections.3
The JEV-specific IgM antibody-capture enzyme-linked
immunosorbent assay (MAC-ELISA) is a sensitive method
of laboratory diagnosis, as JEV IgM is produced soon after
infection and is detectable in 90% of cases in cerebrospinal
fluid (CSF) by 4 days and in serum by 7–9 days after the
onset of clinical illness.4–6 However, JEV is a flavivirus and
the specificity of MAC-ELISA for flaviviruses can be low due
to IgM elicited to other flavivirus infections cross-reacting
with the conserved immunogenic epitopes on the viral anti-
gens used in the ELISA.7 Diagnosis by JEV MAC-ELISA
alone can be problematic in some areas in Asia where JEV
co-circulates with other flaviviruses such as dengue viruses
(DENVs) and West Nile virus (WNV). In addition, DENV
infections infrequently present with neurological symptoms
similar to those of JEV, and dengue (DEN) cases have been
included in acute encephalitis syndrome/acute meningoen-
cephalitis syndrome (AES/AMES) surveillance studies.8,9
The JEV MAC-ELISA is recommended by the World
Health Organization (WHO) to diagnose acute JEV infec-
tions and has been used by the WHO Japanese encephalitis
(JE) laboratory network since 2006 for laboratory-based sur-
veillance of JE and other causes of AES/AMES.10–12 Perfor-
mance of three commercially available JEV MAC-ELISA
kits has been assessed and recommendations to the JE labo-
ratory network on their use has been guided by the results
of these evaluations.13–17 The Panbio JE-Dengue IgM combo
ELISA (Inverness Medical Innovations Inc., Queensland,
Australia) was shown to have superior specificity compared
with the Inbios JE Detect™ MAC-ELISA (JE Detect) (Inbios
International Inc., Seattle, WA) and the JEV CheX (XCyton
Diagnostics Ltd., Bangalore, India) kits because it used a
JEV/DENV quantitative differential diagnostic testing algorithm.
However, Panbio ceased manufacturing the kit in December
2013, and thus an alternative commercial assay or testing algo-
rithm for differential diagnosis of JEV infections was needed.
Inbios International Inc. manufactures two separate MAC-
ELISA kits for JE and DEN diagnosis, the JE Detect and
DEN Detect™ MAC-ELISA (DEN Detect), respectively. Pre-
viously, the JE Detect kit was shown to have low specificity
when DENV IgM+ samples were included in the evalua-
tion sample set.13 However, it was observed at the Centers
for Disease Control and Prevention (CDC) that the DEN
Detect kit had high specificity when JEV IgM+ samples were
included. We wanted to determine if the difference in speci-
ficity between the JE Detect and DEN Detect assays could
be used to differentiate true JEV IgM positives from false
positives (DENV IgM+). A JEV differential testing algorithm
was developed in which samples tested by JE Detect with pos-
itive results were subsequently tested with the DEN Detect
kit, and results of both tests used to make the final interpre-
tation. Positive results in the less specific JE Detect test and
negative results in the specific DEN Detect test would indi-
cate the presence of JEV IgM only, whereas positive results
in both tests would be interpreted as a false positive result
by JE Detect cross-reacting with DENV IgM. The testing
algorithm was evaluated with a reference panel comprised of
JEV IgM+ and DENV IgM+ serum and CSF specimens, as
well as a set of specimens collected during syndromic menin-
goencephalitis (ME) surveillance in Cambodia in 2013.
MATERIALS AND METHODS
Specimens. JE serological reference panel. A panel of 200
sera (60 JEV IgM+, 24 DENV IgM+, five WNV IgM+, 111
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JEV/DENV IgM−) and 75 CSF (24 JEV IgM+, nine DENV
IgM+, and 42 JEV/DENV IgM−) was comprised of archived
diagnostic specimens donated by JE reference and national
network laboratories. The panel was first tested and samples
classified at CDC by JEV and DENV MAC-ELISA and con-
firmed by JEV and DENV 90% plaque reduction neutraliza-
tion assay (PRNT).7,14,15,18,19 A preliminary panel was sent
to four reference laboratories for testing: the National Insti-
tute of Infectious Diseases (NIID), Japan; the National Insti-
tute of Mental Health and Neuro Sciences (NIMHANS),
India; the U.S. Armed Forces Research Institute of Medi-
cal Sciences (AFRIMS), Thailand; and Universiti Malaysia
Sarawak (UNIMAS), Malaysia. The inhouse assays of CDC,
AFRIMS, and UNIMAS used a differential diagnostic test-
ing algorithm that included both JEV and DENV MAC-
ELISA.19–21 However, at AFRIMS and UNIMAS, CSF was
tested only by the JEV IgM ELISA due to the limited sam-
ple volume; UNIMAS classified CSF as JE IgM+, non-JE
flavivirus, and JE IgM−; and AFRIMS classified CSF as JE+
and JE−. Rather than an interpretation of equivocal (EQ),
the NIMHANS assay classifies optical densities that are lower
than the cutoff for JE but higher than the negative cutoff as
non-JE flavivirus; and NIID used a JEV IgM assay only.22
Samples were scored as JEV IgM+ or JEV IgM−. DENV
and WNV IgM+ samples were included in the JE IgM− sub-
set. These samples may have had both JEV and DENV IgM
+ results and were differentiated by PRNT (CDC) or com-
parison of quantitative units (AFRIMS and UNIMAS). Only
samples in which at least four of the five reference labora-
tory results agreed were included in the final reference panel.
No samples with EQ final results were included. Reference
panels were prepared in 2011 with 45 μL volume and stored
at −70°C until use.
Samples from Cambodia National Institute of Public
Health. National public health laboratories that participate in
the WHO JE LabNet test samples using a validated in-house
or commercial assay. All samples with JE positive and EQ
results and about 10% of samples with negative results are
sent to the WHO JE Global Specialized or Regional Refer-
ence laboratories for confirmatory testing as part of the qual-
ity assurance program. Sixty-four samples (25 CSF, 39 sera)
without personal identifiers that had been collected from ME
surveillance patients and tested in Cambodia from 2013 to
2014 with the Panbio kit were sent to CDC for confirmatory
testing.15,19 Samples were tested by CDC JEV and DENV
MAC-ELISA but not all were confirmed by PRNT due to the
limited volume and necessary repeat testing. At CDC, seven
serum samples had JEV+/DENV− results, four had JEV+/
DENV EQ results, and one had a JEV+/DENV+ result.
Because of the limited sample volume, PRNT was carried
out with challenge viruses JEV, DENV-1, and DENV-2, as
DENV-1 serotype was circulating in Cambodia at the time
these samples were collected, and DENV-2 serotype may
cross-react with the other DENV serotypes. This sample was
confirmed as DENV by a 4-fold difference in neutralizing
antibody titer against JEV compared with DENV in the PRNT.
Twenty-five serum samples had negative results in both the
CDC JEV and DENV MAC-ELISA. Two serum samples
had JEV EQ results but no detectable neutralizing antibody
titer, and were also classified as JEV IgM−.15 Of the 25 CSF
samples tested by the CDC JEV and DENV MAC-ELISA
the results were as follows: 15 JEV−/DENV−, three JEV+/
DENV−, three JEV+/DENV EQ, and four JEV+/DENV+.
One CSF sample with JEV+/DENV+ results was confirmed
as JEV+ by PRNT; three had no detectable neutralizing anti-
body titer to JEV, DENV-1, or DENV-2 and could not be
confirmed as either JEV or DENV. The three CSF with JEV
+/DENV EQ results did not have sufficient volume remaining
for PRNT. For these and other samples with JEV+/DENV+
results at CDC, agreement with CDC IgM ELISA results
was the criteria, not final interpretation.
Test methods. CSF and serum sample panels were thawed
once and thereafter stored at 4°C until the testing was com-
pleted. Sera were diluted 1:100 and tested according to the
manufacturer’s instructions in the JE Detect and DEN Detect
kits. A note in the JE Detect kit insert states that CSF can be
tested, but the kit had not been tested or optimized with CSF
and before using the kit one has to optimize the CSF system.
The DEN Detect instructions state that serum is the only sample
type that should be used in the assay. Because of the limited
sample volume, the CSF was diluted 1:10 and tested in single
replicates in both assays. Samples with EQ results were retested,
and those with EQ final results were coded as negative.
The testing algorithm and final interpretations are illus-
trated in Figure 1. Briefly, all samples were tested first by the
JE Detect. Samples with JEV+ results and those with JEV
EQ results that remained EQ upon retesting were tested by
DEN Detect. Samples with DENV EQ results were retested
and EQ final results were coded as negative. Results were
interpreted as shown in Table 1, with final classifications of
JE+ or JE−. Samples with JEV+ and DENV− or EQ results
were interpreted as JE; samples with JEV+ or EQ results
and DENV+ results were interpreted as DEN and classified
as JE−; samples with JEV EQ and DENV− or EQ results
were interpreted as negative and classified as JE−.
RESULTS
Reference serum testing. The 200 serum specimens were
classified by reference laboratory testing as JE+ (N = 60) or
JE− (N = 140); reference DENV IgM+ (N = 24) and WNV
IgM+ (N = 5) samples were included in the JE− subset. All
samples were tested by JE Detect, and those with EQ results
were retested (Table 2). Of the 60 reference JEV IgM+
serum samples, 60 also had positive results in the JE Detect
assay. Of 24 reference DENV IgM+ sera, 23 had positive
results by JE Detect including two samples with JEV EQ
results, which were JEV+ on retesting. One reference DENV
IgM+ sample with JEV EQ results remained JEV EQ after
retesting. Four of the five reference WNV IgM+ samples
(JE−) were negative and one of five was positive by JE Detect.
Of the 111 reference JEV/DENV/WNV IgM− samples, 109
had negative results by JE Detect, including four that were
initially JEV EQ; two samples had JEV EQ results in repli-
cate testing. In summary, based on testing only by JE Detect,
with JEV EQ results coded as negative, concordance with
reference results was 88%, and relative sensitivity and speci-
ficity was 100% and 83%, respectively (Figure 2A).
The 87 sera with JEV+ (N = 84) or EQ (N = 3) results
in JE Detect were later tested DEN Detect (Table 2). The
113 sera with negative results by JE Detect were not tested
further and correctly classified as JE−. Of the 60 reference
JEV IgM+ samples, which were also JEV+ in the JE Detect
assay, 57 had DENV− final results and were correctly classified
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as JE+, including 14 samples with DENV EQ results after
retesting coded as DENV−. Three JE+ serum samples with
positive results in the reference and JE Detect assays had
DENV+ results in the DEN Detect assay, and were therefore
interpreted as DEN and classified as JE−. All 24 of the refer-
ence DENV IgM+ sera, which had JEV+ (N = 23) or EQ
(N = 1) results by JE Detect, were also positive by DEN Detect
and were interpreted as DEN and correctly classified as JE−.
Two reference JEV IgM− samples with JEV EQ results by JE
Detect had negative results by DEN Detect and were coded as
NEG (negative), and correctly classified as JE−. The refer-
ence WNV IgM+ sample with a JEV+ result by JE Detect
had a negative result by DEN Detect, and was therefore
incorrectly interpreted as JE. Final interpretations of the
200 serum samples tested sequentially by JE Detect and DEN
Detect kits, based on the testing algorithm in Figure 1 and
classified as JE+ or JE− according to Table 1, are summa-
rized in Table 2 and Figure 2B. Concordance between refer-
ence test results and those from sequential testing by JE
Detect and DEN Detect kits increased to 98%; relative
FIGURE 1. JE differential diagnostic testing algorithm using JE Detect and DEN Detect kits. Final interpretations, shown at the bottom of the
figure, were made after all testing was completed. Samples with equivocal (EQ) results were retested and those that remained EQ after repeat
testing were coded as NEG. DEN = dengue; DEN Detect = DEN Detect™ MAC-ELISA; DENV = dengue virus; EQ = equivocal; JE = Japanese
encephalitis; JE Detect = JE Detect™ MAC-ELISA; JEV = Japanese encephalitis virus; MAC-ELISA = IgM antibody-capture enzyme-linked
immunosorbent assay; EQ = equivocal; NEG = negative; POS = positive.
TABLE 1
Interpretation of differential diagnostic testing results with sequential testing by JE Detect and DEN Detect kits
JE result DEN result Final interpretation Classification
JEV+ DENV− JE JE+
JEV+ DENV+ DEN JE−
JEV+ DENV EQ (after retest) JE JE+
JEV EQ (after retest) DENV− NEG JE−
JEV EQ (after retest) DENV+ DEN JE−
JEV EQ (after retest) DENV EQ (after retest) NEG JE−
JEV− Not Tested NEG JE−
DEN Detect = DEN Detect™ MAC-ELISA; DENV = dengue virus; EQ = equivocal; JE = Japanese encephalitis; JE Detect = JE Detect™ MAC-ELISA; JEV = Japanese encephalitis virus;
MAC-ELISA = IgM antibody-capture enzyme-linked immunosorbent assay; NEG = negative.
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sensitivity for JE decreased slightly to 95%. Relative speci-
ficity for JE increased to 99%, as the 24 reference DENV+
sera with JEV+ results in JE Detect also had positive results
by DENDetect, and according to the interpretations in Table 1,
they were correctly classified as JE−. Had these samples only
been tested by JE Detect they would have been incorrectly
classified as JE+.
Reference CSF testing. The 75 CSF samples were classi-
fied by reference laboratories as JE+ (N = 24) and JE− (N =
51), including nine CSF that had been confirmed as DENV
IgM+ by PRNT at CDC, but which were not tested by the
other reference laboratories for DENV IgM. Results of test-
ing by JE Detect are shown in Table 2. Of the 24 reference
JEV IgM+ CSF samples, 23 were JEV+ and one was EQ
after retesting by JE Detect. Seven of nine CDC DENV+
CSF were JEV− in JE Detect and two of nine CSF had JEV
EQ initial results and EQ and JEV− results after retesting.
All 42 of the reference JEV/DENV IgM− CSF also had neg-
ative results in JE Detect and were not tested further. Based
on testing only by JE Detect, and coding EQ results as nega-
tive, concordance was 99%, sensitivity was 96%, and speci-
ficity was 100% (Figure 2C).
The 25 CSF with JEV IgM+ (N = 23) or EQ (N = 2)
results by JE Detect were subsequently tested by DEN Detect
(Table 2). Fifteen of 24 reference JEV IgM+ samples had
DENV− or EQ results, and were interpreted as JE and eight
of 24 had positive results by both JE Detect and DEN Detect
and were interpreted as DEN and incorrectly classified as
JE−. The CSF with a JEV EQ result by JE Detect had a nega-
tive result in the DEN Detect assay and was incorrectly classi-
fied as JE−. The CDC DENV IgM+ CSF sample with EQ
result by JE Detect had a NEG result by DEN Detect and
was classified correctly as JE−. According to the testing algo-
rithm, the other eight CDC DENV IgM+ CSF with JEV−
results by JE Detect would not be tested by DEN Detect.
However, to determine the sensitivity of DEN Detect for
TABLE 2
Test results for JEV reference panel samples tested by JE Detect or sequentially by JE Detect and DEN Detect kits compared with reference
laboratory results
Test Interpretation/classification* Reference JEV IgM+ (JE+) Reference DENV IgM+ (JE−) Reference JEV/DENV IgM− (JE−)† Total
Serum
JE Detect JE/JE+ 60 23 1‡ 84
NEG/JE− 0 0 113 113
JEV EQ 0 1 2 3
Total 60 24 116 200
Serum
JE Detect + DEN Detect JE/JE+ 57 0 1‡ 58
DEN/JE− 3 24 0 27
NEG/JE− 0 0 2 2
Total 60 24 3 87
CSF
JE Detect JE/JE+ 23 0 0 23
NEG/JE− 0 8 42 50
JEV EQ 1 1 0 2
Total 24 9 42 75
CSF
JE Detect + DEN Detect JE/JE+ 15 0 0 15
DEN/JE− 8 0 0 8
NEG/JE− 1 9 0 10
Total 24 9 0 33
CSF = cerebrospinal fluid; DEN = dengue; DEN Detect = DEN Detect™ MAC-ELISA; DENV = dengue virus; JE Detect = JE Detect™ MAC-ELISA; EQ = equivocal; JE = Japanese enceph-
alitis; JEV = Japanese encephalitis virus; MAC-ELISA = IgM antibody-capture enzyme-linked immunosorbent assay; NEG = negative.
*Based on Table 1; EQ results after retesting coded as NEG.
†Including five reference WNV IgM+ samples.
‡Reference WNV IgM+.
FIGURE 2. Summary of the comparison of test results of a JE reference serological panel tested either by JE Detect kit alone or sequentially
by JE Detect and DEN Detect according to the testing algorithm in Figure 1. CSF = cerebrospinal fluid; DEN Detect = DEN Detect™ MAC-
ELISA; JE = Japanese encephalitis; JE Detect = JE Detect™ MAC-ELISA; MAC-ELISA = IgM antibody-capture enzyme-linked immunosor-
bent assay.
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CSF samples, all the CDC DENV IgM+ CSF were tested by
DEN Detect and all had negative results. Final interpreta-
tions of the 75 CSF samples tested sequentially by JE Detect
and DEN Detect kits, based on the testing algorithm in
Figure 1 and classified as JE+ or JE− according to Table 1,
are summarized in Table 2. JE concordance decreased to
88%, JE sensitivity decreased to 63%, and JE specificity
remained at 100% when the DEN Detect results were fac-
tored into the interpretations (Figure 2D).
Testing samples from Cambodia National Institute of Pub-
lic Health. A total of 64 samples (39 sera, 25 CSF) were sub-
mitted to CDC for confirmatory testing from Cambodia as
part of the JE laboratory network quality assurance pro-
gram. These samples had been tested with the discontinued
Panbio kit in Cambodia and therefore these results were not
considered. At CDC, samples were tested simultaneously by
CDC JEV and DENV MAC-ELISA then sequentially by JE
Detect and DEN Detect according to the testing algorithm
(Figure 1). Because of the limited sample volume, PRNT
with JEV, DENV-1, and DENV-2 was only carried out on
seven samples with discordant results after the ELISA test-
ing was completed. Ten of 11 of the CDC JEV IgM+ serum
samples were correctly classified as JE+ by JE Detect test-
ing alone (Table 3) and by sequential testing with JE Detect
and DEN Detect (Table 3). One serum sample with JEV/
DENV IgM+ results at CDC, confirmed as DENV+ by
PRNT, also had positive results in the JE Detect and DEN
Detect tests and was interpreted as DEN and correctly classi-
fied JE−. One of 27 serum samples with negative results at
CDC had JEV+ and DENV− results by JE Detect and DEN
Detect tests and was incorrectly classified as JE+. Concor-
dance between CDC reference results and those from testing
only by JE Detector or sequentially by JE Detect and DEN
Detect was 92% and 95%, respectively; relative sensitivity for
both methods was 91%; and specificity was 93% and 96%
(Figure 3).
Results of testing 25 CSF by CDC JEV and DENV MAC-
ELISA were as follows: 15 JEV−/DENV−, three JEV+/
DENV−, three JEV+/DENV EQ, and four JEV+/DENV+.
PRNT was done on the four JEV+/DENV+ CSF; one of
four had neutralizing titer to JEV, but not to DENV 1 and 2
and was classified as JE+. This sample had JEV+ and DENV
EQ results in JE Detect and DEN Detect tests and was cor-
rectly interpreted as JE. The other three CSF had no detect-
able neutralizing antibody to either JEVor DENV. Therefore,
for these three CSF samples, either JEV+ or DENV+ results
in the JE Detect and DEN Detect were considered correct and
concordant with CDC results. Under these criteria, one of
three CSF samples had JEV+ and DENV+ results by JE
Detect and DEN Detect testing, respectively, and was inter-
preted as DEN (JE−) and scored as concordant. Two of three
CSF had JEV+/DENV EQ results by JE Detect and DEN
Detect and were interpreted as JE and were concordant
with CDC results (Table 3). The three CDC JEV+/DENV−
and three CDC JEV+/DENV EQ CSF were also JEV+ and
DENV− in the JE Detect and DEN Detect tests, respec-
tively, and were interpreted as JE and concordant with CDC
results. In summary, a total of nine CSF were classified as
JE+ and one was interpreted as DEN (JE−) (Table 3). One
of the 15 CSF with CDC JEV−/DENV− results was JEV+
and DENV EQ by JE Detect and DEN Detect tests, respec-
tively, and was incorrectly interpreted as JE. Concordance
between CDC results and those from testing only by JE
Detect or sequentially by JE Detect and DEN Detect was
92% and 96%, respectively. Relative sensitivity was 100% for
both testing strategies and relative specificity was 88% and
94% (Figure 3).
DISCUSSION
JE is a vaccine-preventable disease, in contrast to DEN and
WN, for which there are no effective control or treatment
TABLE 3
Comparison of test results for 64 samples from Cambodia NIPH tested sequentially by JE Detect and DEN Detect kits to CDC JEV and DENV
MAC-ELISA results
Interpretation/classification* CDC JEV IgM+ CDC JEV/DENV IgM+† CDCJEV/DENV IgM− Total
Serum
JE Detect JE/JE+ 10 1 1 12
NEG/JE− 0 0 26 26
JEV EQ 1 0 0 1
Total 11 1 27 39
Serum
JE Detect + DEN Detect JE/JE+ 10 0 1 11
DEN/JE− 0 1 0 1
NEG/JE− 1 0 0 26
Total 11 1 1
CSF
JE Detect JE/JE+ 9 1 1 11
NEG/JE− 0 0 14 14
JEV EQ 0 0 0 0
Total 9 1 15 25
CSF
JE Detect + DEN Detect JE/JE+ 9 0 1 10
DEN/JE− 0 1 0 1
NEG/JE− 0 0 0 0
Total 9 1 1 11
CDC = Centers for Disease Control and Prevention; CSF = cerebrospinal fluid; DEN Detect = DEN Detect™ MAC-ELISA; DENV = dengue virus; EQ = equivocal; JE = Japanese encephali-
tis; JE Detect = JE Detect™ MAC-ELISA; JEV = Japanese encephalitis virus; MAC-ELISA = IgM antibody-capture enzyme-linked immunosorbent assay; NEG = negative; PRNT = plaque
reduction neutralization assay.
*Interpretations based on Table 1; EQ results after re-testing coded as NEG.
†Confirmed as DENV+ by plaque reduction neutralization test.
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strategies. Accurate laboratory diagnosis of JEV infections
and differentiation from other flaviviruses with similar clinical
presentation is essential for public health decision making.
JEV-specific MAC-ELISA is more sensitive than JEV RNA
detection, due to the low-level, transient viremia that is gen-
erally cleared by the onset of illness, and the rapid elicitation
of JEV-specific IgM early in acutely ill patients.4–6 CSF is the
preferred specimen for JE diagnosis, as IgM in serum elicited
against other flavivirus infections does not cross into the
CSF.4,6 Also, in cases of neuroinvasive disease, antibodies in
serum may not be the cause of the neurological disease.
However, a single acute serum sample is often the only spec-
imen type obtained as it is often not feasible or safe to col-
lect CSF in clinical settings.
Because of the cross-reactivity of IgM antibodies to the
conserved immunogenic epitopes on the flavivirus envelope
protein, specificity of JEV MAC-ELISA can be low, particu-
larly in areas where multiple flaviviruses co-circulate and the
population is likely exposed.7,9,13,15 This makes laboratory
diagnosis of JEV infection with a single specimen challeng-
ing, even in a reference laboratory. At CDC, the PRNT is
used to confirm MAC-ELISA results and also as a more spe-
cific test to differentiate flavivirus cross-reactivity in primary
flavivirus infections.19 However, in areas where flaviviruses
co-circulate and most flavivirus infections are secondary infec-
tions, neutralizing antibodies from past infections also cross-
react in the PRNT and confound differential diagnostic test
interpretation. In addition, the PRNT is expensive and tech-
nically difficult and thus not a practical test for most labora-
tories with limited resources.
One strategy for reducing flavivirus cross-reactivity is to
make a recombinant antigen in which the consensus epitopes
are removed. However, these cross-reactive epitopes are also
highly immunogenic and removing them may reduce antigen
reactivity, and subsequently, sensitivity. Another method of
differential diagnostic testing is a quantitative ELISA, in which
the IgM titer is calculated into units and each flavivirus in
the test is calibrated against the others, such as in the Panbio
JE/DEN Combo ELISA and AFRIMS in-house assay.4,20
When Panbio announced that it would no longer manufacture
the kit, and in the absence of an alternate commercial JEV
IgM detection assay with similar specificity, another strategy
of JE differential diagnosis was needed, particularly in the
JE LabNet countries where JEV and DENV co-circulate
and DEN cases are included in AMES surveillance.
Inbios developed and optimized two separate MAC-ELISA
assays, JE Detect and DEN Detect. Although there are some
common components, the dilution buffers are different and
cannot be substituted for the other (data not shown), they
have been calibrated separately, and they have different cut-
off values. However, the formats and calculations of the tests
are the same and both use a recombinant virus-like particle
containing the structural membrane and envelope proteins.23
Neither kit has been optimized for CSF, although CSF has
been tested and evaluated in the JE Detect.15 We wanted to
determine if by testing samples sequentially, the specificity of
the JE Detect could be improved. A testing algorithm was
developed in which all samples were first tested by JE Detect
but only samples with positive or EQ results were tested
with the DEN Detect kit. This was more economical than
testing all specimens by both tests simultaneously. In addition,
the specificity criterion was JE+ or JE−; samples with JEV−
results that were true DENV or other flavivirus infections
were not considered.
The majority of serum specimens in the well-characterized
reference panel were correctly identified by testing initially
with the non–JE-specific JE Detect, then with the more spe-
cific DEN Detect. Had the DEN Detect testing not been done,
23 of 24 of reference DENV IgM+ sera which were JEV+ in
JE Detect, would have been have been interpreted as JE.
There is considerable cross-reactivity in the CDC JEV and
DENV MAC-ELISA, which is why the PRNT is an essential
confirmatory test in the CDC differential diagnostic testing
algorithm (Table 4). Thirteen of the 24 reference JEV IgM+
CSF had JEV/DENV IgM+ results at CDC and were con-
firmed as JE+ only by PRNT (4-fold higher neutralization
titer for JE). Included in this subset were the eight CSF with
JEV+/DEN+ results by JE Detect and DEN Detect testing,
respectively (Table 4). Based on CDC JEVand DENV MAC-
ELISA results only, the Inbios JE Detect and DEN Detect
assays had higher specificity for JE. Twelve of 12 JE+ sam-
ples with CDC JEV+/DENV− results and three of 12 JE+
samples with CDC JEV+/DEN+ results (interpreted as inde-
terminate) were correctly classified as JE+ by JE Detect and
FIGURE 3. Summary of the comparison of test results for 64 samples from Cambodia to CDC JEV and DENV MAC-ELISA results as the
reference standard. Samples were tested either by JE Detect kit alone or were sequentially tested by JE Detect and DEN Detect according to the
testing algorithm in Figure 1. CDC = Centers for Disease Control and Prevention; CSF = cerebrospinal fluid; DEN Detect = DEN Detect™
MAC-ELISA; DENV = dengue virus; JE = Japanese encephalitis; JE Detect = JE Detect™ MAC-ELISA; MAC-ELISA = IgM antibody-capture
enzyme-linked immunosorbent assay.
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DEN Detect testing (Table 5). Eight of the nine CDC DEN+
samples were correctly classified as JE− by JE Detect and
DEN Detect testing, including three samples with CDC JEV+/
DENV+ results. However, use of the testing algorithm for
CSF in some cases confounded diagnosis. DEN Detect was
not specific or sensitive for DENV+ CSF, as eight of the
24 reference JEV IgM+ CSF had positive results in DEN
Detect and were interpreted as DEN and classified as (false)
JE− and none of the nine CSF confirmed as DENV+ by
PRNT at CDC were detected by DEN Detect (Table 4). In
contrast, JE Detect had high sensitivity, with 23 of 24 refer-
ence JEV IgM+ CSF having a positive result. In addition,
there was less cross-reactivity in the JE Detect assay to
DENV+ CSF compared with serum samples: one of nine
CSF compared with 23 of 24 in serum. With only eight
CDC-confirmed DENV+ CSF samples, conclusions could not
be made about the accuracy of the testing algorithm with
CSF samples.
The reference panel was comprised of specimens that had
been well-characterized and confirmed at CDC by PRNT.
Samples in which a final determination could not be made,
or those with results that were discordant between the refer-
ence laboratories were excluded. Evaluation of the testing
algorithm was needed with the kind of samples that are tested
in the JE laboratory network; i.e., those collected in surveil-
lance programs or based on clinical diagnosis. The samples
TABLE 5
Comparison of CDC and Inbios CSF test results based on JEV and DENV MAC-ELISA testing only
CDC JE+ CDC DEN+ CDC NEG
TotalJEV+/DENV− JEV+/DEN+* JEV−/DENV+ JEV+/DEN+* JEV/DEN−
JE Detect + DEN Detect Inbios JE+/DEN− 12 3† 1 0 0 16
Inbios JE+/DEN+ 0 8 0 0 0 8
Inbios JE−/DEN− 0 1 5 3 42 51
Total 12 12 6 3 42 75
CDC = Centers for Disease Control and Prevention; CSF = cerebrospinal fluid; DEN Detect = DEN Detect™ MAC-ELISA; DENV = dengue virus; EQ = equivocal; JE = Japanese encephali-
tis; JE Detect = JE Detect™ MAC-ELISA; JEV = Japanese encephalitis virus; MAC-ELISA = IgM antibody-capture enzyme-linked immunosorbent assay; NEG = negative.
*Differential diagnosis determined by 4-fold higher neutralization titer.
†DEN Detect EQ results were coded as NEG.
TABLE 4





















1 18.93 1.23 1:640 1:160 JE+ 64.22 JE 2.20 EQ JE+
2 20.08 1.57 1:4 < 1:4 JE+ 44.83 JE 1.50 NEG JE+
3 17.66 1.67 1:4 < 1:4 JE+ 46.83 JE 1.15 NEG JE+
4 11.93 1.80 1:8 < 1:8 JE+ 67.15 JE 1.23 NEG JE+
5 19.4 3.83 1:640 1:160 JE+ 75.84 JE 3.3 DEN+ DEN+
6 19.07 3.30 1:8 < 1:4 JE+ 83.81 JE 2.25 EQ JE+
7 20.80 3.53 1:4 < 1:4 JE+ 4.68 (4.1) EQ 1.108 NEG NEG
8 19.60 10.76 1:8 < 1:8 JE+ 52.70 JE 6.14 DEN+ DEN+
9 31.02 5.41 1:8 < 1:8 JE+ 86.17 JE 3.20 DEN+ DEN+
10 22.25 4.64 1:160 1:40 JE+ 79.30 JE 2.54 EQ JE+
11 24.11 9.17 1:320 1:80 JE+ 74.34 JE 3.37 DEN+ DEN+
12 22.64 7.64 1:16 < 1:4 JE+ 79.33 JE 3.6 DEN+ DEN+
13 18.87 6.91 1:16 < 1:4 JE+ 68.67 JE 2.3 (2.14) EQ JE+
14 20.68 1.95 1:8 < 1:4 JE+ 73.40 JE 1.36 NEG JE+
15 21.68 3.10 1:4 < 1:4 JE+ 79.58 JE 1.53 NEG JE+
16 27.3 6.16 1:16 < 1:4 JE+ 85.45 JE 3.76 DEN+ DEN+
17 10.87 14.52 1:320 < 1:20 JE+ 84.29 JE 3.34 DEN+ DEN+
18 29.42 7.40 1:160 < 1:20 JE+ 87.49 JE 2.8 (4.15) EQ/DEN+ DEN+
19 6.72 1.20 1:320 < 1:20 JE+ 82.74 JE+ 1.35 NEG JE+
20 6.41 1.77 1:320 1:20 JE+ 48.05 JE 0.96 NEG JE+
21 4.91 1.98 1:320 < 1:20 JE+ 39.63 JE 1.26 NEG JE+
22 3.56 1.68 1:80 < 1:20 JE+ 6.86 JE 2.22 (2.51) EQ JE+
23 3.89 1.00 1:4 < 1:4 JE+ 27.37 JE 1.07 NEG JE+
24 3.99 0.94 1:8 < 1:8 JE+ 53.11 JE 1.08 NEG JE+
25 1.58 2.02 1:40 1:320 DEN+ 4.57 (4.63) EQ 1.03 NEG NEG
26 1.44 2.01 < 1:2 1:320 DEN+ 2.40 NEG 1.02 NEG NEG
27 1.24 3.52 < 1:8 1:8 DEN+ 2.97 NEG 1.44 NEG NEG
28 1.799 3.92 < 1:4 1:4 DEN+ 1.93 NEG 1.02 NEG NEG
29 4.08 5.57 < 1:4 > 1:128 DEN+ 3.84 NEG 1.52 NEG NEG
30 2.84 2.15 < 1:4 1:32 DEN+ 3.71 NEG 1.03 NEG NEG
31 1.02 3.00 < 1:8 1:8 DEN+ 4.8 (2.76) EQ/NEG 2.79 (2.24) EQ NEG
32 2.32 3.46 < 1:4 1:4 DEN+ 2.38 NEG 1.14 NEG NEG
33 1.50 2.96 < 1:4 1:4 DEN+ 2.05 NEG 1.16 NEG NEG
CDC = Centers for Disease Control and Prevention; CSF = cerebrospinal fluid; DEN = dengue; DEN Detect = DEN Detect™ MAC-ELISA; DENV = dengue virus; EQ = equivocal; ISR =
Inbios Detect immune status ratio; JE = Japanese encephalitis; JE Detect = JE Detect™ MAC-ELISA; JEV = Japanese encephalitis virus; MAC-ELISA = IgM antibody-capture enzyme-linked
immunosorbent assay; NEG = negative; P/N = mean OD of sample reacted on viral antigen/mean OD of negative control sample reacted on viral antigen.
*CDC ELISA interpretations: NEG P/N < 2; EQ P/N 2–3; POS, P/N > 3.
†Calculation of JE Detect results: NEG, ISR < 4.0; EQ, ISR 4–6; JE+, ISR > 6.0.
‡Calculation of DEN Detect results: NEG, ISR < 1.65; EQ, ISR 1.65–2.84; DEN+, ISR > 2.84.
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from Cambodia illustrate the difficulty of flavivirus diagnosis
even in reference laboratories. Many of the specimens had
JEV+/DENV+ results in the CDC MAC-ELISA, but few
could be confirmed by PRNT. This was probably because JE
patients, most of them children, are acutely ill and medical
care is sought within the first day or so of onset of illness,
before the neutralizing titer rises to detectable levels. Only
one serum and one CSF sample were confirmed by PRNT as
DEN+ (JE−). These samples did have positive results in the
JE Detect test, but were correctly identified as DEN by DEN
Detect, thus concordance and specificity with CDC results
increased as well.
Although DEN diagnosis generally is not the focus of
AMES surveillance and DENV infections typically have dif-
ferent clinical presentations from neuroinvasive JEV infec-
tions, it has been shown that DEN cases are included in
AMES surveillance either due to the broad clinical definition
of AMES, or because neuroinvasive DENV infections occur
more frequently than previously thought.8 Implementation of
the differential testing algorithm with the JE Detect and DEN
Detect kits may reduce the number of false JE-positive results
reported due to cross-reactivity with DEN cases, particularly
in serum. However, because the numbers of DEN IgM+ CSF
samples in these evaluations was small and the DEN Detect
kit is not intended for CSF testing, further investigation is
warranted before any conclusions can be made on the useful-
ness of the DEN Detect kit for differential diagnosis of JEV
infections with CSF samples.
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